Cancer Chemotherapy and Pharmacology

, Volume 69, Issue 5, pp 1127–1133

A phase I study for adjuvant chemotherapy of gemcitabine plus S-1 in curatively resected patients with biliary tract cancer: adjusting the dose of adjuvant chemotherapy according to the surgical procedures

  • Takeshi Takahara
  • Hiroyuki Nitta
  • Yasushi Hasegawa
  • Naoko Itou
  • Masahiro Takahashi
  • Satoshi Nishizuka
  • Go Wakabayashi
Original Article

DOI: 10.1007/s00280-011-1805-7

Cite this article as:
Takahara, T., Nitta, H., Hasegawa, Y. et al. Cancer Chemother Pharmacol (2012) 69: 1127. doi:10.1007/s00280-011-1805-7

Abstract

Purpose

We conducted a phase I study for adjuvant chemotherapy of gemcitabine (GEM) plus S-1 in order to determine the maximum tolerated dose and the recommended dose (RD) and to evaluate the efficacy and toxicity of the regimen in curatively resected patients with biliary cancer.

Methods

The study included 34 patients with adequate organ functions, Eastern Cooperative Oncology Group PS 0-1, under 80 years of age, who had curative resection after August, 2007. Patients received GEM on day 1 and day 15, and S-1 from day 1 to day 14. Dose-limiting toxicities were determined during first two treatment cycles. After determining RD, a feasibility study was continued in the following four treatment cycles.

Results

Hematological toxicity, particularly neutropenia and thrombocytopenia, was the most pronounced toxic effect of gemcitabine and S-1 adjuvant combination chemotherapy. The RD after pancreatoduodenectomy is GEM 1,000 mg/m2 + S-1 80 mg/m2, and RD after hemihepatectomy is GEM 800 mg/m2 + S-1 60 mg/m2.

Conclusions

The pharmacokinetics of GEM and S-1 indicate that changing the dose of adjuvant chemotherapy based on the operation method for biliary cancers is reasonable. We believe that this regimen will be established as an effective adjuvant chemotherapy for biliary cancer in the future.

Keywords

Biliary tract cancerAdjuvant chemotherapyGemcitabine and S-1Phase I study

Copyright information

© Springer-Verlag 2011

Authors and Affiliations

  • Takeshi Takahara
    • 1
  • Hiroyuki Nitta
    • 1
  • Yasushi Hasegawa
    • 1
  • Naoko Itou
    • 1
  • Masahiro Takahashi
    • 1
  • Satoshi Nishizuka
    • 1
  • Go Wakabayashi
    • 1
  1. 1.Department of SurgeryIwate Medical University School of MedicineMoriokaJapan